Search

Brose, Marcia S

P407

LIBRETTO-531: A PHASE III STUDY OF SELPERCATINIB VS INVESTIGATOR CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH MULTIKINASE INHIBITOR-NAÏVE ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC)

Immunotherapy / Systemic Therapy

Marcia S Brose, MD, PhD1; Jaume Capdevila2; Rossella Elisei3; Lori J Wirth4; Sophie Leboulleux5; Andreas Sashegyi6; Victoria Soldatenkova6; Boris K Lin6; Jennifer Wright6; Bruce Robinson7; Makoto Tahara8; Ana O Hoff9; Mimi Hu10; Eric J Sherman11

1University of Pennsylvania; 2Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron University Hospital; 3University of Pisa; 4Massachusetts General Hospital; 5Gustave Roussy; 6Eli Lilly and Company; 7Royal North Shore Hospital; 8National Cancer Center Hospital East; 9Instituto de Cancer do Estado de Sao Paulo; 10The University of Texas MD Anderson Cancer Center; 11Memorial Sloan Kettering Cancer Center